Rosehip (Rosa canina) for osteoarthritis: the GOPO trials

Rosehip powder containing the galactolipid GOPO has shown modest but reproducible pain relief in hip and knee osteoarthritis across half a dozen randomized trials. Effect size sits between glucosamine and NSAIDs — small enough that it will not impress someone expecting dramatic results, large enough that two systematic reviews now treat it as a legitimate adjunct option.

The active constituent: GOPO

Most of the clinical evidence concerns a standardized Rosa canina powder marketed in Europe as Hyben Vital / LitoZin, which contains a galactolipid identified as (2S)-1,2-di-O-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]-3-O-β-D-galactopyranosyl glycerol — abbreviated GOPO. In vitro work shows GOPO inhibits chemotaxis of peripheral blood neutrophils and reduces CRP-induced upregulation of P-selectin, which provides a plausible anti-inflammatory mechanism distinct from cyclooxygenase blockade.

The pivotal individual trials

Three early Danish-led trials in osteoarthritis of the hip or knee found that rosehip powder 2.5 g twice daily for three to four months reduced WOMAC pain and stiffness scores significantly versus placebo, with NSAID-rescue consumption also dropping in the treatment arms [1][2]. A separate UK trial in 94 patients reported similar pain reductions on the Western Ontario and McMaster index after three months [3].

The meta-analyses

A patient-data meta-analysis pooling three placebo-controlled studies (n=287) reported a standardized mean difference for pain of approximately −0.37 favoring rosehip — a small-to-moderate effect by Cohen's convention, but consistent and statistically robust [4]. A later 2023 Cochrane-style update including additional trials reaffirmed the direction and approximate size of the effect while flagging high heterogeneity in study designs [5].

Head-to-head with glucosamine

One short crossover trial compared rosehip directly to glucosamine in knee OA and found similar reductions in pain on visual analogue scales, with the rosehip arm reporting slightly faster onset (around three weeks versus six weeks for glucosamine) [6]. The trial was small and unblinded, so the comparison is suggestive rather than definitive — but it positions rosehip as in the same broad efficacy bucket as the more familiar joint nutraceuticals.

Cardiometabolic side findings

Several rosehip trials in overweight or obese participants have reported small reductions in systolic blood pressure (~3–4 mmHg) and total cholesterol over six weeks of 40 g/day rosehip drink, with mechanism most likely related to vitamin C, polyphenols, and pectin content rather than GOPO specifically [7]. These are secondary outcomes from small studies and should not drive use.

Safety and practical considerations

Adverse events in trials have been infrequent and mild — primarily gastrointestinal (nausea, loose stools) and skin (rash). The vitamin C content of rosehip is modest at clinical doses; the iron-absorption interaction that concerns some clinicians is unlikely to be material at 2.5 g twice daily. Pregnancy and lactation data are sparse.

The bottom line

Rosehip powder (standardized for GOPO) at 5 g/day is a reasonable evidence-based adjunct for hip or knee osteoarthritis pain. Onset is in the three-to-four-week range, effect size is modest, and the safety profile is favorable. It is not a substitute for weight management, physical therapy, or pharmacologic therapy in moderate-to-severe disease.